Primary trial results show no benefit from anti-TIGIT addition in small cell lung cancer

CHICAGO — Adding tiragolumab, an anti-TIGIT agent, to atezolizumab and carboplatin plus etoposide did not provide more benefit compared with atezolizumab and carboplatin plus etoposide alone, according to findings from SKYSCRAPER-02 trial.
“The IMpower130 trial defined a new standard of care for the treatment of extensive-stage small cell lung cancer, demonstrating a benefit for the addition of the PD-L1 inhibitor atezolizumab to a backbone of carboplatin and etoposide for the treatment of extensive-stage small cell lung cancer,” Charles M. Rudin, MD, chief of thoracic

CHICAGO — Adding tiragolumab, an anti-TIGIT agent, to atezolizumab and carboplatin plus etoposide did not provide more benefit compared with atezolizumab and carboplatin plus etoposide alone, according to findings from SKYSCRAPER-02 trial.
“The IMpower130 trial defined a new standard of care for the treatment of extensive-stage small cell lung cancer, demonstrating a benefit for the addition of the PD-L1 inhibitor atezolizumab to a backbone of carboplatin and etoposide for the treatment of extensive-stage small cell lung cancer,” Charles M. Rudin, MD, chief of thoracic